Q: What is the general mission of Cell Signaling Technology, Inc.?
James Cullem: Cell Signaling Technology, Inc. is a family-owned, private company encompassing more than 400 employees globally. The company has grown over the last decade to become the recognized worldwide leader in the development of innovative and high-quality reagents for studying cellular signaling pathways, and their defects that underlie most cancers and other diseases. The company has also developed proprietary discovery technologies that have impacted on the drug development and diagnostics fields, including identification of novel diagnostic biomarkers and drug targets.
Q: When was Cell Signaling Technology founded?
James Cullem: Cell Signaling Technology was launched in 1999 as a spin-out of New England Biolabs, Inc. (Ipswich, MA) by scientists interested and focused in tumor biology and developing better reagents for its study. The two companies, sharing family co-ownership, still have a close business relationship, although their areas of product focus are distinct.